MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair
MBX Biosciences, Inc. (MBX)
Company Research
Source: GlobeNewswire
CARMEL, Ind., Jan. 22, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Laurie Stelzer as an independent director on the Company’s Board of Directors and as chairperson of the board’s audit committee. Ms. Stelzer brings decades of executive and financial leadership experience with extensive corporate governance, financial oversight, and accounting experience. “I am thrilled to welcome Laurie Stelzer to the Company’s Board as an independent director,” said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences. “Laurie adds significant expertise as an audit committee chair and business leader, and her commercial and strategic proficiency complements the deep experience of our Board. We look forward to working closely with her
Show less
Read more
Impact Snapshot
Event Time:
MBX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MBX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MBX alerts
High impacting MBX Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
MBX
News
- MBX Biosciences (NASDAQ:MBX) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.MarketBeat
- MBX Biosciences (NASDAQ:MBX) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.MarketBeat
- Assessing MBX Biosciences (MBX) Valuation After A 261% One Year Total Shareholder Return [Yahoo! Finance]Yahoo! Finance
- MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
MBX
Earnings
- 11/6/25 - Beat
MBX
Sec Filings
- 1/22/26 - Form 4
- 1/22/26 - Form 3
- 1/22/26 - Form 8-K
- MBX's page on the SEC website